TD201

AssetAlso 1% sirolimus cream

Topical formulation of sirolimus that selectively inhibits mTOR complex 1.

Stage: Phase 1
Modality: Small molecule
Target: Autophagy; 1
Indication: 535
Trials: 1
Developer

Indications

1

Pachyonychia congenita
Phase 1, Completed, NCT02152007, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains4
Owner and partners1
Trials535
Evidence for its targets4
Competitors2
Aging relevance4
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.